New research from OMRF is taking physicians closer to personalized treatment solutions for patients suffering from lupus.
Arthritis is the leading cause of disability in adults in the U.S. Understandably, this has led to much concern about the future of arthritis treatment.
Scientists at OMRF have made new findings that could pave the way for the first drug to treat aortic stenosis.
David Key had never heard of sarcoidosis—until the rare disease stole his health.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
The project will focus on comparing certain immune cells in patients with Sjögren’s to those of healthy controls.